The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

but investors pulled back due to a "pause" in a trial of key product in development. Boston Scientific's (NYSE: BSX) stock was down just over 1% as of 3:30, after it fell as far as 4% earlier in ...

Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...

“We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.” Boston Scientific increased its full-year ...

Vijay Kumar, an analyst at Evercore, said in an interview that Farapulse is likely Boston Scientific’s most important product from Wall Street’s perspective. The pulsed field ablation system ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the ...

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Yet, with launches from J&J and Medtronic on the horizon, Needham analysts said Boston Scientific’s electrophysiology growth will slow significantly in 2025. With PFA competition set to increase, ...